Search research articles
Contact Us
Filters
Showing results (411-420 of 454) with videos related to
Page
of 46
Sort By:
Annals of Surgery
|
January 25, 2006
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy
Anees B Chagpar, Lavinia P Middleton, Aysegul A Sahin, et al.
Cancer Cell
|
February 12, 2015
14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2
Jia Xu, Sunil Acharya, Ozgur Sahin, et al.
Cancer
|
June 7, 2005
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study
Alberto J Montero, Roman Rouzier, Ana Lluch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2013
Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer
J Q Chen, Y Bao, J Lee, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 4, 2002
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy
Thomas A Buchholz, Angela Katz, Eric A Strom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2000
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer
T M Breslin, L Cohen, A Sahin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2011
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy
Phuong K Morrow, Gerburg M Wulf, Joe Ensor, et al.
Cancer Discovery
|
July 11, 2013
DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition
Nanyue Chen, Seetharaman Balasenthil, Jacquelyn Reuther, et al.
Cancer Research
|
January 24, 2025
Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer
Tanvi H Visal, Recep Bayraktar, Petra den Hollander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2007
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen
Aman U Buzdar, Vicente Valero, Nuhad K Ibrahim, et al.
Page
of 46
Search research articles
Search
Showing results (411-420 of 454) with videos related to
Sort By:
Page
of 46
Annals of Surgery
|
January 25, 2006
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy
Anees B Chagpar, Lavinia P Middleton, Aysegul A Sahin, et al.
Cancer Cell
|
February 12, 2015
14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2
Jia Xu, Sunil Acharya, Ozgur Sahin, et al.
Cancer
|
June 7, 2005
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study
Alberto J Montero, Roman Rouzier, Ana Lluch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 5, 2013
Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer
J Q Chen, Y Bao, J Lee, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 4, 2002
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy
Thomas A Buchholz, Angela Katz, Eric A Strom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2000
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer
T M Breslin, L Cohen, A Sahin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 7, 2011
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy
Phuong K Morrow, Gerburg M Wulf, Joe Ensor, et al.
Cancer Discovery
|
July 11, 2013
DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition
Nanyue Chen, Seetharaman Balasenthil, Jacquelyn Reuther, et al.
Cancer Research
|
January 24, 2025
Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer
Tanvi H Visal, Recep Bayraktar, Petra den Hollander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 4, 2007
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen
Aman U Buzdar, Vicente Valero, Nuhad K Ibrahim, et al.
Page
of 46